|
| Authors |
Title |
Citation |
Core tip / conclusive remarks |
|
|
| Tanaka K, Brown S, Goyal M, Menon BK, Campbell BCV, Mitchell PJ, Jovin TG, Saver JL, Muir KW, White PM, Bracard S, Guillemin F, Roos YBWEM, van Zwam WH, Najm M, Dowlatshahi D, Hill MD, Demchuk AM; HERMES Collaborators. |
HERMES-24 Score Derivation and Validation for Simple and Robust Outcome Prediction After Large Vessel Occlusion Treatment. |
Stroke. 2024 Aug; 55(8):1982-1990. |
The post-treatment HERMES-24 score is a simple validated score that predicts a 3-month outcome after anterior circulation large vessel occlusion stroke regardless of intervention, which helps prognostic discussion with families on day 2. |
|
| Siddiqi AZ, Kashani N, Dmytriw AA, Yavagal DR, Saposnik G, Tymianski M, Adams C, Hill MD, Dowlatshahi D, Katsanos AH, Menon BK, Ganesh A, Singh N. |
Cytoprotective agents in stroke: Still uncertainty in the next frontier. |
J Stroke Cerebrovasc Dis. 2024 Sep; 33(9):107860. |
Pharmacologic interactions result in major uncertainty about cytoprotective treatment choices. |
|
| Dammavalam V, Lin S, Nessa S, Daksla N, Stefanowski K, Costa A, Bergese S. |
Neuroprotection during Thrombectomy for Acute Ischemic Stroke: A Review of Future Therapies. |
Int J Mol Sci. 2024 Jan 10; 25(2):891. |
Advances in multiple neuroprotective therapies, including uric acid, activated protein C, nerinetide, otaplimastat, imatinib, verapamil, butylphthalide, edaravone, nelonemdaz, ApTOLL, regional hypothermia, remote ischemic conditioning, normobaric oxygen, and especially nuclear factor erythroid 2-related factor 2, have promising evidence for improving stroke care. |
|
| Kim H, Choi S, Kim DE. |
Preclinical Replication Study of the Postsynaptic Density Protein-95 Inhibitor Nerinetide. |
J Clin Neurol. 2024 May; 20(3):330-332. |
The present study does suggest that implementing multicenter animal studies is warranted to enhance the reproducibility and generalizability of preclinical observations. |
|
| Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM, Poppe AY, Buck BH, Field TS, et al; ESCAPE-NA1 Investigators. |
Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double blind, randomized controlled trial. |
Lancet. 2020 Mar 14; 395(10227):878-887. |
Nerinetide, an eicosapeptide that interferes with post-synaptic density protein 95, is a neuroprotectant that is effective in preclinical stroke models of ischemia-reperfusion. Nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. |
|
|
